|
SWIS |
MANAGEMENT’S DISCUSSION & ANALYSIS FORM 51-102F1 FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2019 |
MD&A (Management Discussion and Analysis) |
14/11/2019 |
 Open Filing (246.74 KB) |
|
SWIS.WT |
MANAGEMENT’S DISCUSSION & ANALYSIS FORM 51-102F1 FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2019 |
MD&A (Management Discussion and Analysis) |
14/11/2019 |
Open Filing (246.74 KB) |
|
SWIS |
CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2019 AND 2018 |
Quarterly Listing Statement |
14/11/2019 |
Open Filing (377.19 KB) |
|
SWIS.WT |
CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2019 AND 2018 |
Quarterly Listing Statement |
14/11/2019 |
Open Filing (377.19 KB) |
|
VPH |
VALEO PHARMA ANNOUNCES FILING OF A NEW DRUG SUBMISSION FOR LOW MOLECULAR WEIGHT HEPARIN IN CANADA |
Press Release |
14/11/2019 |
Open Filing (156.15 KB) |
|
BAMM |
Audited Annual Consolidated Financial Statements For the Year Ended July 31, 2019 |
Audited Annual Financial Statements |
13/11/2019 |
Open Filing (629.55 KB) |
|
PRIM |
Management Information Circular |
Management Proxy/Information Circular |
13/11/2019 |
Open Filing (608.21 KB) |
|
TCAN |
Certificate of Compliance |
Certificate of compliance |
13/11/2019 |
 Open Filing (18.84 KB) |
|
LLL |
Lanebury Provides Bi-Weekly Status Update Regarding Management Cease Trade Order |
Press Release |
13/11/2019 |
Open Filing (131.29 KB) |
|
RIN |
Form 5 Quarterly Listing Statement - Q3 2019 |
Quarterly Listing Statement |
13/11/2019 |
Open Filing (1.56 MB) |
